Evaluation of Pain Treatment After Total Knee Arthroplasty
ConditionPain
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorVertex Pharmaceuticals Incorporated
About this trial
The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m²)
Scheduled to undergo an elective primary unilateral TKA surgery
Disqualifiers
None
Trial design
Design model
Sequential
Treatments tested in this trial
Suzetrigine
DrugTablets for oral administration.
Placebo
DrugPlacebo matched to SUZ for oral administration
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: Suzetrigine (SUZ)Experimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Total Opioid Usage
Time frame
24 hours to 168 hours after the first dose of study drugSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov